Determination of the risk factors for breast cancer survival using the Bayesian method, Yazd, Iran

Pahlevani, Vida; Mohammadzadeh, Morteza; Pahlevani, Nima; Nayeb Zadeh, Vajiheh

Determination of the risk factors for breast cancer survival using the Bayesian method, Yazd, Iran

Document Type : Original Article

Authors

¹ Department of Biostatistics and Epidemiology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

² Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

³ Department of Medical Sciences, Kashan University, Kashan, Iran

Abstract

Background: There are numerous sophisticated studies which have investigated risk factors of breast cancer (BC). The purpose of this paper is to use benefits of Bayesian modeling to involve such prior information in determining factors affecting the survival of women with BC in Yazd city. Materials and Methods: The checklist included the characteristics of the patients and the factors studied. Then, from the records of patients referred to Radiotherapy Center of Shahid Ramezanzadeh, who had BC, from April 2005 to March 2012, the survival of 538 persons was recorded in the census. Data were analyzed by R software version 3.4.2, and 0.05 was considered the significance level. Results: The mean age of BC diagnosis was 48.03 ± 11016 years. The Bayesian Cox regression showed that surgery (hazard ratio [HR] =1.631 95% PI; 1.102–2.422), ki67 (HR = 3.260. 95% PI; 1.6308–6.372), stage (HR = 5.620, 95% PI; 4.079–7.731), lymph node (HR = 1.765, 95% PI; 1.127–2.790), and ER (HR = 2. 600 95% PI; 2.023–3.354) were significantly related to survival time. Conclusion: The parametric and cox models were compared with standard error, and Cox model was selected as an optimal model. Accordingly, stage, ki67, lymph node, ER, and surgery variables had a positive effect on death hazard.

Keywords

References

1.	Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 2015;526:131-5.
2.	Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: Systematic review and meta-analysis to update the 2009 US preventive services task force recommendation effectiveness of breast cancer screening. Ann Intern Med 2016;164:244-55.
3.	Kazemi A, Omid E, Amin MM, Nesaee P. A Survey on breast cancer status in Kurdistan province on Medical Geography viewpoint During 2006 - 2010.hsr. 2015;11:459–72.
4.	Potosky AL, O'Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, et al. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer 2015;121:4062-70.
5.	McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet (London, England). 2014;383:2127–35.
6.	Jafari-Koshki T, Schmid VJ, Mahaki B. Trends of breast cancer incidence in Iran during 2004-2008: A Bayesian space-time model. Asian Pac J Cancer Prev 2014;15:1557-61.
7.	Sharifian A, Pourhoseingholi MA, Emadedin M, Rostami Nejad M, Ashtari S, Hajizadeh N, et al. Burden of breast cancer in Iranian women is increasing. Asian Pac J Cancer Prev 2015;16:5049-52.
8.	Cleves M, Gould W, Gould WW, Gutierrez R, Marchenko Y. An Introduction to Survival Analysis Using Stata, Second Edition. Stata Press; 2008. 398p.
9.	Cox DR, Oakes D. Analysis of Survival Data. Boca Raton: Chapman and Hall/CRC; 2017. 212 p. Bennett S. Analysis of survival data by the proportional odds model. Stat Med 1983;2:273-7.
10.	Klein JP, Houwelingen HC van, Ibrahim JG, Scheike TH. Handbook of Survival Analysis. CRC Press; 2016. 635p.
11.	Zhou H, Hanson T. spBayesSurv: Bayesian Modeling and Analysis of Spatially Correlated Survival Data. R Package Version; 2014. p. 1.
12.	Kabacoff RI. R in action: Data analysis and graphics with R. Simon and Schuster; 2015.
13.	Plummer M, Best N, Cowles K, Vines K. CODA: Convergence diagnosis and output analysis for MCMC. R News. 2006 Mar; 6:7–11.
14.	Therneau TM. Extending the Cox Model. In: Lin DY, Fleming TR, editors. Proceedings of the First Seattle Symposium in Biostatistics. New York, NY: Springer US; 1997. p. 51–84. (Lecture Notes in Statistics).
15.	Elandt-Johnson RC, Johnson NL, Statistiker M. Survival models and data analysis. Wiley Online Library; 1980.
16.	Tazhibi M, Fayaz M, Mokarian F. Detection of prognostic factors in metastatic breast cancer. J Res Med Sci 2013;18:283-90.
17.	Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
18.	Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, et al. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of clinical pathology. 2015;68:839–43.
19.	Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010;1:747-54.
20.	Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984;54:2436-40.
21.	Moslemi D, Gholizadeh PA, Hajian K, Sum SH, Pourghasem M, Jahantigh R. Comparison of Modified Radical Mastectomy with Breast Conservative Therapy and Radiotherapy in Patients with Breast Cancer; 2012.
22.	Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM. Influence of tumour stage at breast cancer detection on survival in modern times: Population based study in 173,797 patients. BMJ 2015;351:h4901.
23.	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
24.	Ren Y, Black DM, Mittendorf EA, Liu P, Li X, Du XL, et al. Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. PLoS One 2014;9:e110281.
25.	Vostakolaei FA, Broeders MJ, Rostami N, van Dijck JA, Feuth T, Kiemeney LA, et al. Age at Diagnosis and Breast Cancer Survival in Iran. Simon MS, editor. International Journal of Breast Cancer. 2012 Nov 22;2012:517976.
26.	Khodarahmi S, Rezaianzadeh A. The role of prognostic factors on the survival of breast cancer patients: Bayesian approach. Iran J Epidemiol 2015;11:23-33.
27.	Fallahzadeh H, Momayyezi M, Akhundzardeini R, Zarezardeini S. Five year survival of women with breast cancer in Yazd. Asian Pac J Cancer Prev 2014;15:6597-601.
28.	de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, '. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial. BMC Cancer 2017;17:379.
29.	Haghighat S. Survival rate and its correlated factors in breast cancer patients referred to Breast Cancer Research Center. Iran J Breast Dis 2013;6:28-36.
30.	Ibrahim JG, Chen MH, Sinha D. Bayesian semiparametric models for survival data with a cure fraction. Biometrics 2001;57:383-8.
31.	Othus M, Mitchell A, Barlogie B, Morgan G, Crowley J. Cure-Rate Survival Models and Their Application to Cancer Clinical Trials. In: Matsui S, Crowley J, editors. Frontiers of Biostatistical Methods and Applications in Clinical Oncology [Internet]. Singapore: Springer; 2017. p. 165-78. Available from: https://doi.org/10.1007/978-981-10-0126-0_11. [Last accessed on 2021 Jun 26].
32.	Haghighat S. Survival rate and its correlated factors in breast cancer patients referred to Breast Cancer Research Center. Iran J Breast Dis. 2013;6:28¨C36.
33.	Ibrahim JG, Chen M-H, Sinha D. Bayesian survival analysis. Wiley Online Library; 2005.
34.	Othus M, Mitchell A, Barlogie B, Morgan G, Crowley J. Cure-Rate Survival Models and Their Application to Cancer Clinical Trials. Front Biostat Methods Appl Clin Oncol. Springer; 2017. p. 165¨C178.

Advanced Biomedical Research